Fouquet G, Wartski M, Dechmi A, et al. - This study was carried out to evaluate the predictive impact of PET parameters in prognosis of relapse/refractory multiple myeloma (RRMM) patients before initiating antiCD38 therapy. Researchers enrolled consecutive RRMM patients who had undergone baseline 18F-FDG PET /CT before anti-CD38 based immunotherapy (Daratumumab, Isatuximab) in our centre between June 2019 and December 2020. They calculated survival functions using Kaplan Meier estimates, comparisons between categories were made with the log-rank test. They used Mann-Whitney U test to compare PET variables in relation to beta2microglobuline (B2M). The study enrolled a total of 38 patients (female n = 19) with a median age at relapse of 73 (range 58 - 87). The results showed that the presence of > 3 FLs on PET/CT is a predictor of survival outcomes in patients with relapse/refractory MM treated with CD38 targeted therapy and correlates with tumour burden biomarker.